The estimated Net Worth of Sandford D Smith is at least $1.47 Million dollars as of 2 September 2022. Mr. Smith owns over 11,369 units of Cytokinetics Inc stock worth over $1,265,692 and over the last 13 years he sold CYTK stock worth over $0. In addition, he makes $199,654 as Independent Director at Cytokinetics Inc.
Sign up
Mr. Smith CYTK stock SEC Form 4 insiders trading
Sandford has made over 17 trades of the Cytokinetics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 11,369 units of CYTK stock worth $268,991 on 2 September 2022.
The largest trade he's ever made was exercising 29,032 units of Cytokinetics Inc stock on 19 November 2021 worth over $382,351. On average, Sandford trades about 2,913 units every 11 days since 2012. As of 2 September 2022 he still owns at least 23,539 units of Cytokinetics Inc stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sandford Smith biography
Sandford D. Smith is Independent Director of the Company. Mr. Smith has served as a member of our Board of Directors since March 2012. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 to 2011, Mr. Smith held various positions at Sanofi-Genzyme (formerly Genzyme Corporation), most recently leading the integration of Genzyme’s international business into Sanofi’s global organization. Prior to that, he served as Executive Vice President of Genzyme Corporation and President of Genzyme International. From 1986 to 1996, Mr. Smith was President, Chief Executive Officer and a member of the Board of Directors of RepliGen Corporation. From 1977 to 1985, Mr. Smith held various positions at Bristol-Myers Squibb, most recently serving as Vice President of Business Development and Strategic Planning for the Pharmaceutical and Nutritional Division. Mr. Smith has served on the Board of Directors of Akcea Therapeutics, Inc. since March 2017 and Neuralstem, Inc. since May 2014. He served on the Board of Directors of Arpicus Biosciences, Inc. from August 2014 to February 2019, Novelion Therapeutics Inc. from November 2016 to March 2017, Aegerion Pharmaceuticals, Inc. from January 2012 to March 2017 and NVenta Biopharmaceuticals Corporation from 2007 to 2009. Mr. Smith earned a B.S. from the University of Denver. Mr. Smith brings to our Board of Directors broad experience in matters relating to the launch and commercialization of new drugs in a wide range of therapeutic areas, and in particular drugs targeting rare disease indications. He also has extensive experience as a public company executive and board member in the pharmaceutical and biotechnology industries.
What is the salary of Sandford Smith?
As the Independent Director of Cytokinetics Inc, the total compensation of Sandford Smith at Cytokinetics Inc is $199,654. There are 15 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.
How old is Sandford Smith?
Sandford Smith is 73, he's been the Independent Director of Cytokinetics Inc since 2012. There are 3 older and 17 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.
What's Sandford Smith's mailing address?
Sandford's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Insiders trading at Cytokinetics Inc
Over the last 20 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi..., and Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.
What does Cytokinetics Inc do?
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
What does Cytokinetics Inc's logo look like?
Complete history of Mr. Smith stock trades at Cytokinetics Inc and Akcea Therapeutics Inc
Cytokinetics Inc executives and stock owners
Cytokinetics Inc executives and other stock owners filed with the SEC include:
-
Robert Blum,
President, Chief Executive Officer, Director -
Fady Malik,
Executive Vice President - Research and Development -
Mark Schlossberg,
Senior Vice President, General Counsel, Secretary -
Ching Jaw,
Chief Financial Officer, Senior Vice President -
David Cragg,
Chief Human Resource Officer, Chief Administrative Officer -
Robert I. Blum,
CEO, Pres & Director -
Dr. Fady Ibraham Malik,
Exec. VP of R&D -
Mark A. Schlossberg,
Sr. VP of Legal, Gen. Counsel & Sec. -
Ching W. Jaw,
Sr. VP & CFO -
David W. Cragg,
Chief HR & Admin. Officer -
Leonard Patrick Gage,
Independent Chairman of the Board -
Wendall Wierenga,
Independent Director -
B. Lynne Parshall,
Independent Director -
John Henderson,
Independent Director -
Santo Costa,
Independent Director -
Sandford Smith,
Independent Director -
Edward Kaye,
Independent Director -
Robert Califf,
Independent Director -
Nancy Wysenski,
Independent Director -
Diane Weiser,
IR Contact Officer -
Robert Wong,
Chief Accounting Officer, Vice President -
Kari K. Loeser J.D.,
VP & Chief Compliance Officer -
Robert Wong,
VP & Chief Accounting Officer -
Jeff Lotz,
VP of Sales & Operations -
Dr. James A. Spudich Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Bradley Paul Morgan,
SVP Drug Discovery & Early Dev -
Caryn Gordon Mc Dowell,
GC & Chief Compliance Officer -
Elisabeth Schnieders,
Sr. VP, Business Development -
L Patrick Gage,
Director -
Bonnie Charpentier,
SVP Regulatory & Compliance -
Robert Arthur Harrington,
Director -
Associates Vi Lp Srb,
10% owner -
Sung Lee,
EVP, Chief Financial Officer -
Peter S Roddy,
SVP Finance & CAO -
Muna Bhanji,
Director -
Michael Rabson,
SVP Business Dev/Legal & GC -
A Grant Iii Heidrich,
Director -
Mark Mcdade,
Director -
Brett A Pletcher,
EVP, Chief Legal Officer -
Sharon Barbari,
Sr. VP, Finance & CFO -
Charles J Homcy,
Director -
James H Sabry,
President and CEO -
David J Jr Morgans,
SVP-Drug Discovery and Dev -
James A Spudich,
Director -
Michael Schmertzler,
Director -
Jay K Trautman,
VP, Technology -
Stephen M Dow,
Director -
Denise Gilbert,
Director -
Capital Ltd Portfolio Servi...,
-
Suisse First Boston/Credit ...,
-
John Vdomenik Stephen Lbayl...,
-
William J Rutter,
Director -
Ixmayfield Ix Management Ll...,
-
Rosen Vii Affiliates Fund L...,
10% owner -
Associates Vii Lp Srb,
10% owner -
Associates Viii Lp Srb,
10% owner -
Rosen Viii Affiliates Fund ...,
10% owner -
Rosen Fund Viii Lp Sevin,
10% owner -
Rosen Fund Vi Lp Sevin,
10% owner -
Rosen Fund Vii Lp Sevin,
10% owner -
Rosen Vi Affiliates Fund Lp...,
10% owner -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Andrew Callos,
EVP, Chief Commercial Officer